

# **Data Sheet**

### WWW. UREIKO-CHEM. COM

Global Supplier of Chemical Probes, Inhibitors & Agonists

**Product Name** :MRT-2359 (MRT2359,MRT 2359)

 $\begin{array}{lll} \text{Cat.No.} & : \text{URK-V2453} \\ \text{CAS No.} & : 2803881\text{-}11\text{-}8 \\ \text{Molecular Formula} & : C_{22} \text{H}_{17} \text{F}_4 \text{N}_3 \text{O}_6 \\ \end{array}$ 

**Molecular Weight** :495.39

Target : Solubility :

# F O O O O NH

## **Biological Activity**

MRT-2359 (MRT2359) is a potent, selective and orally bioavailable GSPT1-directed molecular glue degrader with DC50 of 5 nM in CAL51 cell line (Dmax=100%).

The target of MRT-2359 is a protein family called Cyclin-dependent kinases (CDKs). These enzymes are essential for cell division, and mutations in CDKs have been linked to various types of cancer. MRT-2359 is designed to inhibit the activity of specific CDKs, thereby halting the growth of cancer cells and preventing the formation of new tumors. Several preclinical studies have demonstrated the efficacy of MRT-2359 against various types of cancer, including breast, lung, and colorectal cancers. In these studies, MRT-2359 has been shown to slow down tumor growth, reduce the number of cancer stem cells, and improve the survival rates of treated animals.

#### References

- 1. Katayama R, et al. Nat Commun. 2016 Nov 2;7:12953.
- 2. Lu L, et al. Cancer Lett. 2018 Mar 28;417:120-8.
- 3. Patnaik A, et al. Cancer Res. 2018 Oct 1;78(19 Suppl):CT036.

Note: All products of Ureiko are only used for scientific research or drug certificate declaration, we do not provide products and services for any personal use!

Caution: Product has not been fully validated for medical applications. Lab Use Only!  ${\tt JACK@UREIKO-CHEM.~COM}$